83bar has entered a strategic collaboration with Virgo Surgical Video Solutions for launching a new Constellation Platform for the recruitment of patients into clinical trials.

Merging the key video recording platform and VirgoTrials suite of tools with the 83bar Patient Activation system, this clinical trial recruitment and engagement platform will expedite recruitment into trials.

Constellation will aid practice managers and trial sponsors in connecting different aspects of the recruitment process.

Virgo Surgical Video Solutions Life Sciences vice-president Craig Darlin said: “This new technology platform can accelerate study recruitment by connecting only protocol-qualified and ready-to-act patients to clinical trial sites and keeping patients engaged to prevent costly dropout.”

The Constellation Platform provides a combined patient journey management. It assesses endoscopy videos for inclusion/exclusion measures, detects qualifying inclusion profiles, and connects the patient to a clinical agent.

It subsequently educates and monitors them, prepares informed consent, and schedules back for an assessment.

The platform also aids clinical specialists in boosting care within their practices and helps to maintain more patients.

It performs additional work for site coordinators, offering lowered screen failures and efficiently meeting trial quotas.

This approach results in primary investigators concluding trials to get findings published rapidly.

The platform also helps trial sponsors in detecting further real-world candidates from clinical monitoring, boosting confidence in qualifications that are based on real-world criteria, and enhancing diversity from real-world patient groups.

83bar CEO Bob Baurys said: “This first-of-its-kind patient recruitment platform integrates Virgo’s ability to analyse endoscopy videos to identify patients using an industry-recognised artificial intelligence algorithm. 

“Then, potential candidates receive rapid outreach from the 83bar clinical contact centre to educate them about local clinical trial options and screenings based upon specific indication criteria.”